GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1D
16. okt., 16:56:00 GMT -3 · BRL
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GILD34 …
Odpri
66,36 BRL
Visoka
66,41 BRL
Nizka
65,81 BRL
Tržna kapitalizacija
193,67 mrd.
Povprečni promet
261,00
Promet
1,78 tis.
52-tedenski najvišji tečaj
67,38 BRL
52-tedenski najnižji tečaj
51,33 BRL
Št. izdanih delnic
1,24 mrd.
Št. zaposlenih
17 tis.
Odpri
66,36 BRL
Visoka
66,41 BRL
Nizka
65,81 BRL
Tržna kapitalizacija
193,67 mrd.
Povprečni promet
261,00
Promet
1,78 tis.
52-tedenski najvišji tečaj
67,38 BRL
52-tedenski najnižji tečaj
51,33 BRL
Št. izdanih delnic
1,24 mrd.
Št. zaposlenih
17 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Yahoo Finance
·
pred 8 urami
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
pred 9 urami
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
pred 1 dnevom
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
pred 1 dnevom
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Vizitka: Gilead Sciences Inc BDR
Generalni direktorDaniel O'Day
Št. zaposlenih17 tis.
Ustanovljeno22. jun. 1987
SedežFoster City, Kalifornija, Združene države Amerike
Sektor-
Spletno mestogilead.com